Company Overview
Snapshot
Founded in January 2021 by Dr. Amir Zlotkin and Bruno Grandsard, DisperseBio operates with 1–10 employees. The company has raised $1 million across two funding rounds from three investors.
Business overview
DisperseBio develops materials to combat microbial contamination caused by biofilms across critical sectors and healthcare systems. Leveraging 15 years of research and five patent families, the company's core technology involves synthetic peptides designed to activate natural microbial biofilm dispersion. These non-toxic, eco-friendly, and economically viable solutions target industries such as desalination, cooling systems, oil and gas corrosion control, water treatment, ship hull coating, and drip irrigation systems, aiming to improve energy efficiency and reduce production losses.
Log in to access full profile ›Company Intelligence Q&A
- What is DisperseBio's primary focus?
- DisperseBio focuses on developing natural anti-biofilm and biofouling solutions to combat microbial contamination in critical industrial and healthcare sectors. Their technology aims to reduce energy consumption and production losses caused by biofilms.
- Who founded DisperseBio?
- DisperseBio was founded by Dr. Amir Zlotkin and Bruno Grandsard in January 2021.
- What is the total capital raised by DisperseBio?
- DisperseBio has raised a total of $1 million across two funding rounds.
- What kind of technology does DisperseBio utilize?
- DisperseBio utilizes biomimetic synthetic peptides that activate a natural microbial biofilm dispersion process. This technology is non-toxic and eco-friendly, offering an alternative to traditional antimicrobials.